

Oncology FISH Service

Contact details:

Bristol Genetics Laboratory
Pathology Sciences
Southmead Hospital
Bristol, BS10 5NB
Enquiries : 0117 414 6168
FAX: 0117 414 6464

Head of Department:
Eileen Roberts FRCPath

Head of Oncology Genomics:
Chris Wragg FRCPath

Service Lead:

Abby Palmer
Email: Abigail.Palmer@nbt.nhs.uk

Sample Requirements:

Bone marrow and peripheral blood samples in transport media or Lithium Heparin

Fresh tissue in transport media or saline (no formalin)

FFPE: 4 µm thick formalin fixed paraffin embedded tumour tissue sections mounted on APES or 'sticky' slides for each test required with an accompanying H&E slide with regions of tumour highlighted.

All samples should be labelled with patient name, date of birth and pathology block number.

Samples should be accompanied by a FULLY completed request form (available as download at www.nbt.nhs.uk/genetics or from the laboratory).

Consent and Storage: (DNA and Cultured Cells)

All genetic testing requires consent. It is the responsibility of the referring clinician to ensure that appropriate consent has been obtained.

Stored material from all referrals may be retained for quality assurance purposes and maybe used anonymously for the development of new tests for the disorder in question.

Introduction

FISH is used in Oncology to support diagnosis, provide prognostic information for risk stratification, allow tracking of disease status and monitoring transplant and treatment success.

Service offered

We offer a range of testing using CE marked probes. Additional testing can be developed on request; please contact the laboratory if there are any further tests required that are not listed below.

Disease	Abnormality	Probe Set
Adipocytic tumours	MDM2 amplification	MDM2
ALL	t(9;22)	BCR/ABL1
	t(12;21)	ETV6/RUNX1 (TEL/AML1)
	11q23 translocation	KMT2A (MLL)
	12p13 rearrangements	ETV6 (TEL)
	19p13 rearrangements	E2A (TCF3)
Alveolar rhabdomyosarcoma	PAX3-FOXO1 [t(2;13)] PAX7-FOXO1 [t(1;13)]	FOXO1(FKHR)
AML	t(8;21)	RUNX1/RUNX1T1 (ETO/AML1)
	t(15;17)	PML/RARA
	inv(16)	CBFB
	11q23 translocation	MLL
AML/MDS	del(5q), monosomy 5	EGR1/D5S23, D5S721
	del(7q), monosomy 7	D7S522/CEP7 (D7Z1)
	del(20q)	20q- (PTPRT 20q12)/20q11
	t(3;3) or inv(3)	MECOM (EV11)
Anaplastic Lymphoma	NPM-ALK (+variants)	ALK
	DUSP22/IRF4	DUSP22
Angiomatoid fibrous histiocytoma	EWSR1-CREB1	EWSR1
	FUS-ATF1	FUS
APML	t(15;17)	PML/RARA
BMT	Sex mismatch transplant	CEPX/CEPY
Burkitt Lymphoma/HGBL	MYC [t(8;14) and variants]	MYC, MYC/ IGH
	BCL6 (3q27)	BCL2
	BCL2 (18q21)	BCL6
CLL	TP53 deletion	TP53/ATM
	Trisomy 12, del(13)	12CEN/D13S319/13q34
	11q deletion	ATM/TP53
	t(11;14)	IGH/CCND1
CML	t(9;22)	BCR/ABL
Desmofibrosarcoma protruberans	t(17;22)	COL1A1/PDGFRB
DLBCL/HGBL	MYC (8q24)	MYC
	BCL6 (3q27)	BCL6
	BCL2 (18q21)	BCL2
Ew ings sarcoma	t(11;22) and variants	EWSR1 FUS

Oncology FISH Service

Contact details:

Bristol Genetics Laboratory
Pathology Sciences
Southmead Hospital
Bristol, BS10 5NB
Enquiries: 0117 414 6168
FAX: 0117 414 6464

Head of department:

Eileen Roberts FRCPath

Head of Oncology Genetics:

Chris Wragg FRCPath

Service Lead:

Abby Palmer
Email: Abigail.Palmer@nbt.nhs.uk

Sample Requirements:

Bone marrow and peripheral blood samples in transport media or Lithium Heparin

Fresh tissue in transport media or saline (no formalin)

4 µm thick formalin fixed paraffin embedded tumour tissue sections mounted on APES or 'sticky' slides for each test required with an accompanying H&E slide with regions of tumour highlighted.

All samples should be labelled with patient name, date of birth and pathology block number.

Samples should be accompanied by a FULLY completed request form (available as download at www.nbt.nhs.uk/genetics or from the laboratory).

Consent and Storage: (DNA and Cultured Cells)

All genetic testing requires consent. It is the responsibility of the referring clinician to ensure that appropriate consent has been obtained.

Stored material from all referrals may be retained for quality assurance purposes and may be used anonymously for the development of new tests for the disorder in question.

Follicular lymphoma	t(14;18)	BCL2
HES	PDGFRA	FIP1L1-CHIC2-PDGFRB
	PDGFRB	PDGFRB
	FGFR1	FGFR1
	BCR-ABL1	BCR-ABL1
Low -grade fibromyxoid sarcoma	FUS-CREB3L2/1	FUS
MALT	t(11;18)	MALT1
Mantle cell Lymphoma	t(11;14)	IGH/CCND1
Mammary Analogue secretory carcinoma	ETV6-NTRK3	ETV6
MPN/MDS	PDGFRA	FIP1L1-CHIC2-PDGFRB
	PDGFRB	PDGFRB
	FGFR1	FGFR1
	BCR-ABL1	BCR-ABL1
Myeloma	del(17)	p53
	t(4;14)	IGH/FGFR3
	t(14;16)	IGH/MAF
	1p32.3/1q21	CKS1B/CDKN2C
Myxoid liposarcoma	FUS-DDIT3 EWSR1-DDIT3	DDIT3 (CHOP), FUS EWSR1
NSCLC	ALK-EML4 and variants	ALK FISH/IHC
Synovial sarcoma	SS18-SSX	SS18

Target Reporting Time

Urgent/rapid referrals ≤3 calendar days

Routine referrals ≤21 days

FFPE samples ≤14 days

Please contact the laboratory for up to date prices

Quality

The laboratory is CPA accredited and participates in UK NEQAS schemes.

Laboratory Contact

For enquiries/requesting contact Abigail.Palmer@nbt.nhs.uk